Background: There is increased recognition that cancers of the upper GI tract comprise
distinct epidemiological and molecular entities. Erlotinib has shown activity in patients with …

Purpose A phase II trial of the oral epidermal growth factor receptor (EGFR) inhibitor erlotinib
in patients with gastroesophageal adenocarcinomas stratified according to primary tumor …

Background There is no standard systemic therapy for metastatic esophageal cancer
progressing after 1st/2nd line chemotherapy (Thallinger et al, 2011, JCO, 4709-14). High …

Background Evidence is scarce for the effectiveness of therapies for oesophageal cancer
progressing after chemotherapy, and no randomised trials have been reported. We aimed to …

4021 Background: At presentation, most cases of adenocarcinoma of the oesophagus
(ACO) are inoperable and, although chemotherapy with cisplatin/5-fluorouracil can prolong …

Background: Concurrent chemoradiotherapy is a valuable treatment option for localised
oesophageal cancer (EC), but improvement is still needed. A randomised phase II trial was …

Importance Standard first-line regimens for patients with metastatic gastroesophageal
adenocarcinomas have an approximate 40% objective response rate (ORR). The …

BACKGROUND: Tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor
(EGFR) have activity in solid tumors. The authors evaluated an oral EGFR TKI, erlotinib, in …

Background EGFR overexpression occurs in 27–55% of oesophagogastric
adenocarcinomas, and correlates with poor prognosis. We aimed to assess addition of the …

4006 Background: ECF (epirubicin, cisplatin, fluorouracil), IC (irinotecan, cisplatin), and
FOLFOX (leucovorin, fluorouracil, oxaliplatin) are commonly used regimens for …